[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20040808A1 - Derivados de urea ciclica como inhibidores de quinasas - Google Patents

Derivados de urea ciclica como inhibidores de quinasas

Info

Publication number
PE20040808A1
PE20040808A1 PE2004000090A PE2004000090A PE20040808A1 PE 20040808 A1 PE20040808 A1 PE 20040808A1 PE 2004000090 A PE2004000090 A PE 2004000090A PE 2004000090 A PE2004000090 A PE 2004000090A PE 20040808 A1 PE20040808 A1 PE 20040808A1
Authority
PE
Peru
Prior art keywords
imidazolidine
trifluoromethanosulfonyl
ilmethyl
trifluoroacetate
phenyl
Prior art date
Application number
PE2004000090A
Other languages
English (en)
Inventor
Marcel Patek
Anil Nair
Augustin Hittinger
Conception Nemecek
Daniel Bond
Greg Harlow
Herve Bouchard
Jacques Mauger
Jean-Luc Malleron
Mark Palermo
Fahad Al-Obeidi
Thomas Faitg
Hartmut Strobel
Sven Ruf
Kurt Ritter
Youssef El-Ahmad
Dominique Lesuisse
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20040808A1 publication Critical patent/PE20040808A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE P ES 0 A 2; R Y R1 SON O, NH; R2 Y R3 SON HIDROGENO, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO Y HETEROARILO EVENTUALMENTE SUBSTITUIDO O R2 Y R3 FORMAN JUNTOS CON EL CARBONO A LOS CUALES ESTAN UNIDOS UN RADICAL CARBOCICLICO O HETEROCICLICO, ENTRE OTROS; A1 ES UN ENLACE SENCILLO, ALQUILO, ALQUENILO, ALQUINILO; Y E Y1 SON H, OCF3, S(O)nCF3, O-CF2-CHF2, -O-CHF2, ENTRE OTROS; Y E Y1 SON H, HALO, OH, NR5R6 ENTRE OTROS; R5 Y R6 SON HIDROGENO, ALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS O R5 Y R6 FORMAN CON EL N AL CUAL ESTAN UNIDOS UN RADICAL HETEROCICLICO, ENTRE OTROS; A2 REPRESENTAN LOS VALORES DE A1 Y CO Y S02; B2 ES HETEROCICLICO SATURADO O NO SATURADO CONTENIENDO UNO A VARIOS HETEROATOMOS, ENTRE OTROS; Y2 ES H, HALOGENO, HIDROXILO, ALQUILO, ALCOXI, ENTRE OTROS. n ES 0 A 2. SON COMPUESTOS PREFERIDOS TRIFLUOROACETATO DE (S)-5-METIL-1-QUINOLIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL)-IMIDAZOLIDINO-2,4-DIONA, TRIFLUOROACETATO DE (S)-5-METIL-1-PIRIDIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL)- IMIDAZOLIDINO-2,4-DIONA, TRIFLUOROACETATO DE (S)-5-METIL-1-QUINOLIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL) IMIDAZOLIDINO-2,4-DIONA, TRIFLUOROACETATO DE (R)-4-METIL-3-QUINOLIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL)-IMIDAZOLIDINO-2-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE QUINASAS (GRUPO FAK) UTILES PARA TRATAMIENTOS EN ONCOLOGIA
PE2004000090A 2003-01-31 2004-01-22 Derivados de urea ciclica como inhibidores de quinasas PE20040808A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (fr) 2003-01-31 2003-01-31 Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
PE20040808A1 true PE20040808A1 (es) 2004-12-31

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000090A PE20040808A1 (es) 2003-01-31 2004-01-22 Derivados de urea ciclica como inhibidores de quinasas

Country Status (24)

Country Link
EP (1) EP1599464B1 (es)
JP (1) JP4604020B2 (es)
KR (1) KR20050098286A (es)
CN (1) CN1768054A (es)
AR (1) AR042936A1 (es)
AT (1) ATE482207T1 (es)
AU (1) AU2004209319A1 (es)
BR (1) BRPI0407091A (es)
CA (1) CA2513631A1 (es)
DE (1) DE602004029236D1 (es)
FR (1) FR2850652B1 (es)
HR (1) HRP20050679A2 (es)
MA (1) MA27651A1 (es)
ME (1) MEP22608A (es)
MX (1) MXPA05007407A (es)
NO (1) NO20054006L (es)
NZ (1) NZ541270A (es)
PE (1) PE20040808A1 (es)
PL (1) PL377811A1 (es)
RS (1) RS20050657A (es)
RU (1) RU2341523C2 (es)
TW (1) TW200505898A (es)
WO (1) WO2004070050A2 (es)
ZA (1) ZA200505934B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2384753T3 (en) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2004305075A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ES2378778T5 (es) 2005-05-13 2015-09-25 The Regents Of The University Of California Compuesto de diarilhidantoína
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PT3412290T (pt) 2006-03-27 2021-04-19 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US8093254B2 (en) 2006-12-12 2012-01-10 Schering Corporation Aspartyl protease inhibitors
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
US20120122889A1 (en) 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
WO2011103202A2 (en) 2010-02-16 2011-08-25 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2655428B1 (en) * 2010-12-21 2022-09-14 Cytec Technology Corp. Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
HUE051211T2 (hu) 2012-09-26 2021-03-01 Aragon Pharmaceuticals Inc Antiandrogének nem áttétes, kasztrációrezisztens prosztatarák kezelésére
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
AU2015206652A1 (en) 2014-01-14 2016-08-04 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
SI3487851T1 (sl) * 2016-07-20 2022-03-31 Novartis Ag Derivati aminopiridina in njihova uporaba kot selektivni zaviralci ALK-2
EP4438126A2 (en) 2017-10-16 2024-10-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019088677A1 (ko) * 2017-10-31 2019-05-09 광주과학기술원 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
CN1249748A (zh) * 1997-03-03 2000-04-05 贝林格尔·英格海姆药物公司 用于治疗炎症疾病的小分子
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
CN1209358C (zh) * 2000-05-31 2005-07-06 田边制药株式会社 αLβ2介导细胞粘连的抑制剂
ES2572808T3 (es) * 2002-05-16 2016-06-02 Merial, Inc. Derivados de piridincarboxamida y su utilización como plaguicidas

Also Published As

Publication number Publication date
MEP22608A (en) 2010-06-10
FR2850652B1 (fr) 2008-05-30
NZ541270A (en) 2008-11-28
BRPI0407091A (pt) 2006-01-24
FR2850652A1 (fr) 2004-08-06
AR042936A1 (es) 2005-07-06
HRP20050679A2 (en) 2006-12-31
WO2004070050A2 (fr) 2004-08-19
NO20054006L (no) 2005-10-13
PL377811A1 (pl) 2006-02-20
JP2006517569A (ja) 2006-07-27
JP4604020B2 (ja) 2010-12-22
DE602004029236D1 (de) 2010-11-04
RU2005127335A (ru) 2006-09-10
ZA200505934B (en) 2007-06-27
KR20050098286A (ko) 2005-10-11
TW200505898A (en) 2005-02-16
RS20050657A (en) 2007-06-04
NO20054006D0 (no) 2005-08-29
WO2004070050A3 (fr) 2005-02-17
EP1599464B1 (fr) 2010-09-22
AU2004209319A1 (en) 2004-08-19
RU2341523C2 (ru) 2008-12-20
MA27651A1 (fr) 2005-12-01
EP1599464A2 (fr) 2005-11-30
CA2513631A1 (fr) 2004-08-19
ATE482207T1 (de) 2010-10-15
CN1768054A (zh) 2006-05-03
MXPA05007407A (es) 2005-09-12

Similar Documents

Publication Publication Date Title
PE20040808A1 (es) Derivados de urea ciclica como inhibidores de quinasas
PE20060556A1 (es) Derivados de urea ciclicos sustituidos con heterociclo como inhibidores de quinasa
PE20221253A1 (es) Inhibidores de pequenas moleculas de mutante g12c de kras
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
UA81468C2 (en) Heteroarylcarbamoylbenzene derivatives
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
BR0209334A (pt) Aminas n-aroil cìclicas
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20040934A1 (es) Derivados de pirimidina como inhibidores selectivos de tirosina quinasas
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
ES2590504T3 (es) N-ciclilamidas como nematicidas
ECSP066298A (es) Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3)
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
ES2391373T3 (es) Derivados de quinoleína como inhibidores de la cinasa AXL
DE60007329D1 (de) N-heterozyklische derivate als nos inhibitoren
PE20040156A1 (es) 2-heteroaril-pirimidinas como inhibidores de quinasa dependiente de ciclina
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
DE69836422D1 (de) N-heterocyclische derivate als nos inhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed